MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 574044 | Name: Alaproclate HCl
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Alaproclate HCl is a selective serotonin reuptake inhibitor (SSRI). It inhibits depletion of serotonin (5-HT) induced by 4-methyl-α-ethyl-m-tyramine in rat cerebral cortex, hippocampus, hypothalamus, and striatum. Alaproclate inhibits NMDA-evoked currents and depolarization-induced voltage-dependent potassium currents in rat hippocampal neurons.

Chemical Structure

Alaproclate HCl
CAS#60719-83-7 (HCl)

Theoretical Analysis

MedKoo Cat#: 574044

Name: Alaproclate HCl

CAS#: 60719-83-7 (HCl)

Chemical Formula: C13H19Cl2NO2

Exact Mass: 291.0793

Molecular Weight: 292.20

Elemental Analysis: C, 53.44; H, 6.55; Cl, 24.26; N, 4.79; O, 10.95

Price and Availability

Size Price Availability Quantity
5mg USD 250.00 4 Weeks
10mg USD 450.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
57469-92-8 ( S isomer HCl) 66171-75-3 ( S isomer) 60719-83-7 (HCl) 60719-82-6 (free base)
Synonym
Alaproclate HCl, GEA 654, GEA654, GEA-654
IUPAC/Chemical Name
1-(4-chlorophenyl)-2-methylpropan-2-yl alaninate
InChi Key
OPAKSOWFKIUFNP-UHFFFAOYSA-N
InChi Code
InChI=1S/C13H18ClNO2.ClH/c1-9(15)12(16)17-13(2,3)8-10-4-6-11(14)7-5-10;/h4-7,9H,8,15H2,1-3H3;1H
SMILES Code
NC(C)C(OC(C)(C)CC1=CC=C(Cl)C=C1)=O.[H]Cl
Appearance
A crystalline solid
Purity
>95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 292.20 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Ogren SO, Holm AC, Hall H, Lindberg UH. Alaproclate, a new selective 5-HT uptake inhibitor with therapeutic potential in depression and senile dementia. J Neural Transm. 1984;59(4):265-88. doi: 10.1007/BF01255596. PMID: 6205120. 2: Wilkinson A, Courtney M, Westlind-Danielsson A, Hallnemo G, Akerman KE. Alaproclate acts as a potent, reversible and noncompetitive antagonist of the NMDA receptor coupled ion flow. J Pharmacol Exp Ther. 1994 Dec;271(3):1314-9. PMID: 7996440. 3: Teunissen MW, Wahlén A, Vinnars E, Breimer DD. Influence of alaproclate on antipyrine metabolite formation in man. Eur J Clin Pharmacol. 1984;27(4):447-52. doi: 10.1007/BF00549593. PMID: 6519152. 4: Ross SB. Further studies on the high-affinity binding of 3H-alaproclate to membranes from rat liver and some other tissues. Pharmacol Toxicol. 1990 Mar;66(3):170-5. doi: 10.1111/j.1600-0773.1990.tb00727.x. PMID: 2333272. 5: Frost SJ, Eccleston D, Marshall EF, Hassanyeh F. Alaproclate--an open clinical study in depressive illness. Psychopharmacology (Berl). 1984;83(3):285-7. doi: 10.1007/BF00464796. PMID: 6433393. 6: Bergman I, Bråne G, Gottfries CG, Jostell KG, Karlsson I, Svennerholm L. Alaproclate: a pharmacokinetic and biochemical study in patients with dementia of Alzheimer type. Psychopharmacology (Berl). 1983;80(3):279-83. doi: 10.1007/BF00436170. PMID: 6412274. 7: Svensson BE, Werkman TR, Rogawski MA. Alaproclate effects on voltage- dependent K+ channels and NMDA receptors: studies in cultured rat hippocampal neurons and fibroblast cells transformed with Kv1.2 K+ channel cDNA. Neuropharmacology. 1994 Jun;33(6):795-804. doi: 10.1016/0028-3908(94)90119-8. PMID: 7936117. 8: Rawłów A, Pawłowski L, Przegaliński E. Alaproclate: further pharmacological evidence for 5-HT uptake inhibition in vivo. Arch Int Pharmacodyn Ther. 1983 Oct;265(2):219-29. PMID: 6651410. 9: Dehlin O, Hedenrud B, Jansson P, Nörgård J. A double-blind comparison of alaproclate and placebo in the treatment of patients with senile dementia. Acta Psychiatr Scand. 1985 Feb;71(2):190-6. doi: 10.1111/j.1600-0447.1985.tb01270.x. PMID: 3883697. 10: Altman HJ, Nordy DA, Ogren SO. Role of serotonin in memory: facilitation by alaproclate and zimeldine. Psychopharmacology (Berl). 1984;84(4):496-502. doi: 10.1007/BF00431456. PMID: 6241314. 11: Alberts P, Ogren SO. Effects of alaproclate, potassium channel blockers, and lidocaine on the release of 3H-acetylcholine from the guinea-pig ileum myenteric plexus. Pharmacol Toxicol. 1989 Jul;65(1):25-32. doi: 10.1111/j.1600-0773.1989.tb01121.x. PMID: 2780505. 12: Aberg-Wistedt A, Alvariza M, Bertilsson L, Malmgren R, Wachtmeister H. Alaproclate a novel antidepressant? A biochemical and clinical comparison with zimeldine. Acta Psychiatr Scand. 1985 Mar;71(3):256-68. doi: 10.1111/j.1600-0447.1985.tb01282.x. PMID: 2580422. 13: Ogren SO, Nordström O, Danielsson E, Peterson LL, Bartfai T. In vivo and in vitro studies on the potentiation of muscarinic receptor stimulation by alaproclate, a selective 5-HT uptake blocker. J Neural Transm. 1985;61(1-2):1-20. doi: 10.1007/BF01253047. PMID: 2984330. 14: Ross SB. Proadifen-sensitive high affinity binding of 3H-alaproclate to liver membranes. Pharmacol Toxicol. 1987 Nov;61(5):282-7. doi: 10.1111/j.1600-0773.1987.tb01819.x. PMID: 3438220. 15: Hu PS, Ross SB. NMDA receptor-mediated increase in cyclic GMP in the rat cerebellum in vivo is blocked by alaproclate and GEA-857. Pharmacol Toxicol. 1997 Feb;80(2):97-102. doi: 10.1111/j.1600-0773.1997.tb00290.x. PMID: 9060041. 16: Brodin E, Ogren SO, Theodorsson-Norheim E. Effects of subchronic treatment with imipramine, zimelidine and alaproclate on regional tissue levels of substance P- and neurokinin A/neurokinin B-like immunoreactivity in the brain and spinal cord of the rat. Neuropharmacology. 1987 Jun;26(6):581-90. doi: 10.1016/0028-3908(87)90151-1. PMID: 2439937. 17: Sommerfelt L, Hauge ER, Ursin R. Similar effect on REM sleep but differential effect on slow wave sleep of the two 5-HT uptake inhibitors zimeldine and alaproclate in cats and rats. J Neural Transm. 1987;68(1-2):127-44. doi: 10.1007/BF01244644. PMID: 2949058. 18: Hedlund B. Alaproclate affects membrane ion channels in GH3/B6 pituitary cells. Pharmacol Toxicol. 1987 Oct;61(4):236-41. doi: 10.1111/j.1600-0773.1987.tb01810.x. PMID: 2448764. 19: Rosén A, Franck J, Brodin E. Effects of acute systemic treatment with the 5 HT-uptake blocker alaproclate on tissue levels and release of substance P in rat periaqueductal grey. Neuropeptides. 1995 Jun;28(6):317-24. doi: 10.1016/0143-4179(95)90096-9. PMID: 7545268. 20: Ogren SO, Holm AC. Test-specific effects of the 5-HT reuptake inhibitors alaproclate and zimelidine on pain sensitivity and morphine analgesia. J Neural Transm. 1980;47(4):253-71. doi: 10.1007/BF01247321. PMID: 6446594.